Highlights
1. High Response Rates in Refractory Disease
The study reported an overall response rate (ORR) of 76% (19 of 25 patients), which is significantly higher than historical benchmarks for relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL).
2. Manageable Safety Profile
While haematological adverse events were common (84% grade 3 or worse neutropenia), no treatment-related deaths occurred, and the regimen was well-tolerated across the 15-70 age range.
3. Sustained Efficacy
With a median follow-up of 31.8 months, the trial provides robust evidence for the durability of response in a subset of patients, supporting its role as a bridge to further therapy or transplant.
Background: The Clinical Challenge of Relapsed T-ALL
T-cell acute lymphoblastic leukaemia (T-ALL) remains one of the most challenging subtypes of acute leukaemia to treat in the relapsed or refractory setting. Unlike B-cell ALL, which has seen a revolution through blinatumomab, inotuzumab ozogamicin, and CAR-T cell therapies, T-ALL treatment options have remained largely stagnant. Conventional intensive chemotherapy regimens often result in low response rates and high toxicity, leading to a median survival of less than six months for patients who fail primary induction.
Recent advances in molecular biology have identified BCL-2 as a critical survival factor in T-cell precursors. Early T-cell precursor (ETP) ALL and certain subsets of T-ALL exhibit high levels of BCL-2 expression, making them theoretically sensitive to venetoclax, a potent BCL-2 inhibitor. While venetoclax has transformed the treatment landscape for acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL), its role in T-ALL has primarily been documented in retrospective series and case reports. This phase 2 trial provides the first prospective, multicentre evidence for the combination of venetoclax and azacitidine in this specific patient population.
Study Design and Methodology
This multicentre, single-arm, phase 2 trial (NCT05149378) enrolled 25 patients between November 2021 and December 2024. The study population included patients aged 15 to 70 years with relapsed or refractory T-ALL. Inclusion criteria required an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, ensuring the results could be generalized to a broader clinical population than most restrictive phase 1 trials.
The intervention consisted of a synergistic combination of venetoclax and azacitidine. Venetoclax was administered with a ramp-up dose to mitigate the risk of tumour lysis syndrome: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21. Azacitidine was administered subcutaneously at 75 mg/m2 per day for the first seven days of each cycle. The primary endpoint was the overall response rate (ORR), which encompassed complete remission (CR), complete remission with partial haematological recovery (CRp), complete remission with incomplete haematological recovery (CRi), and morphological leukaemia-free state (MLFS).
Key Findings: Rapid and Deep Clinical Responses
The trial achieved its primary endpoint with an impressive ORR of 76%. Among the 25 enrolled patients, nine (36%) achieved complete remission, four (16%) achieved CRp, four (16%) achieved CRi, and two (8%) achieved MLFS. This level of activity is particularly noteworthy given the refractory nature of the disease in many participants.
The median follow-up time was 31.8 months, providing a longitudinal look at the outcomes that is often missing from early-phase leukaemia trials. The study was conducted entirely within an Asian population, with a median age of 39.0 years, reflecting a younger adult demographic that often struggles with the long-term toxicities of traditional intensive chemotherapy.
Safety and Adverse Events
The safety profile was consistent with the known effects of venetoclax-based regimens in other myeloid malignancies, characterized primarily by haematological toxicity. Grade 3 or worse adverse events included:
- Neutropenia: 84% (21/25)
- Anaemia: 44% (11/25)
- Febrile Neutropenia: 40% (10/25)
- Thrombocytopenia: 20% (5/25)
- Infections: 12% (3/25)
Crucially, there were no treatment-related serious adverse events or deaths reported during the study period. This suggests that the venetoclax plus azacitidine regimen is significantly safer and more manageable than high-dose salvage chemotherapy like FLAG-Ida, which often carries a high risk of treatment-related mortality in the relapsed setting.
Expert Commentary: Mechanistic Insights and Clinical Utility
The high efficacy of venetoclax in T-ALL is biologically plausible. T-cell development is heavily regulated by the BCL-2 family of proteins. In particular, immature T-cells depend on BCL-2 for survival, whereas more mature T-cells shift toward BCL-XL dependence. This biological gradient explains why patients with ETP-ALL or early-stage T-ALL phenotypes often show the most dramatic responses to venetoclax-based therapy.
Despite the positive results, the study has limitations. As a single-arm trial with 25 patients, it lacks a direct comparator. Furthermore, the inclusion of only Asian patients may necessitate further validation in other ethnic groups to ensure global generalizability. However, the depth of response and the safety profile make this regimen an attractive option for bridging patients to allogeneic haematopoietic stem cell transplantation (HSCT), which remains the only curative option for relapsed T-ALL.
Conclusion: A New Pillar in T-ALL Salvage Therapy
The venetoclax plus azacitidine regimen represents a significant step forward in the treatment of relapsed or refractory T-ALL. By providing a 76% response rate with a manageable toxicity profile, it offers a viable alternative to intensive chemotherapy for patients who have limited options. Clinicians should consider this regimen for patients who are candidates for salvage therapy, particularly those who may not tolerate high-dose anthracyclines or cytarabine. Future randomized trials are now required to determine if this combination should be moved into the frontline setting or combined with other novel agents like nelarabine or proteasome inhibitors.
Funding and Trial Registration
This study was funded by the National Natural Science Foundation of China. It is registered with ClinicalTrials.gov under the identifier NCT05149378.
